PubMed

Highly active antiretroviral therapy in a large urban clinic: risk factors for virologic failure and adverse drug reactions.

Lucas GM, Chaisson RE, Moore RD.

Ann Intern Med. 1999 Jul 20;131(2):81-7.PMID: 10419445 [PubMed - indexed for MEDLINE]Related articlesFree article

Virologic outcome and predictors of virologic failure of highly active antiretroviral therapy containing protease inhibitors.

Knobel H, Guelar A, Carmona A, Espona M, González A, López-Colomés JL, Saballs P, Gimeno JL, Díez A.

AIDS Patient Care STDS. 2001 Apr;15(4):193-9.PMID: 11359661 [PubMed - indexed for MEDLINE]Related articles

Treatment history and baseline viral load, but not viral tropism or CCR-5 genotype, influence prolonged antiviral efficacy of highly active antiretroviral treatment.

Bratt G, Karlsson A, Leandersson AC, Albert J, Wahren B, Sandström E.

AIDS. 1998 Nov 12;12(16):2193-202.PMID: 9833861 [PubMed - indexed for MEDLINE]Related articles

Predictors of virological success and ensuing failure in HIV-positive patients starting highly active antiretroviral therapy in Europe: results from the EuroSIDA study.

Paredes R, Mocroft A, Kirk O, Lazzarin A, Barton SE, van Lunzen J, Katzenstein TL, Antunes F, Lundgren JD, Clotet B.

Arch Intern Med. 2000 Apr 24;160(8):1123-32.PMID: 10789605 [PubMed - indexed for MEDLINE]Related articlesFree article

Lopinavir/ritonavir: a review of its use in the management of HIV infection.

Cvetkovic RS, Goa KL.

Drugs. 2003;63(8):769-802. Review.PMID: 12662125 [PubMed - indexed for MEDLINE]Related articles

Factors associated with sustained virologic suppression in patients receiving antiretroviral therapy in an urban HIV care clinic.

Purkayastha T, Wasi F, Shuter J.

AIDS Patient Care STDS. 2005 Dec;19(12):785-93.PMID: 16375610 [PubMed - indexed for MEDLINE]Related articles

Study of the impact of HIV genotypic drug resistance testing on therapy efficacy.

Van Vaerenbergh K.

Verh K Acad Geneeskd Belg. 2001;63(5):447-73. Review.PMID: 11813503 [PubMed - indexed for MEDLINE]Related articles

Dual vs single protease inhibitor therapy following antiretroviral treatment failure: a randomized trial.

Hammer SM, Vaida F, Bennett KK, Holohan MK, Sheiner L, Eron JJ, Wheat LJ, Mitsuyasu RT, Gulick RM, Valentine FT, Aberg JA, Rogers MD, Karol CN, Saah AJ, Lewis RH, Bessen LJ, Brosgart C, DeGruttola V, Mellors JW; AIDS Clinical Trials Group 398 Study Team.

JAMA. 2002 Jul 10;288(2):169-80.PMID: 12095381 [PubMed - indexed for MEDLINE]Related articlesFree article

HIV RNA and CD4 cell count response to protease inhibitor therapy in an urban AIDS clinic: response to both initial and salvage therapy.

Deeks SG, Hecht FM, Swanson M, Elbeik T, Loftus R, Cohen PT, Grant RM.

AIDS. 1999 Apr 16;13(6):F35-43.PMID: 10397555 [PubMed - indexed for MEDLINE]Related articles

Treatment with highly active antiretroviral therapy in human immunodeficiency virus type 1-infected children is associated with a sustained effect on growth.

Verweel G, van Rossum AM, Hartwig NG, Wolfs TF, Scherpbier HJ, de Groot R.

Pediatrics. 2002 Feb;109(2):E25.PMID: 11826235 [PubMed - indexed for MEDLINE]Related articlesFree article

Predictors of virologic failure in HIV-1-infected patients starting highly active antiretroviral therapy in Porto Alegre, Brazil.

Tuboi SH, Harrison LH, Sprinz E, Albernaz RK, Schechter M.

J Acquir Immune Defic Syndr. 2005 Nov 1;40(3):324-8.PMID: 16249707 [PubMed - indexed for MEDLINE]Related articles

Regimen simplification to atazanavir-ritonavir alone as maintenance antiretroviral therapy after sustained virologic suppression.

Swindells S, DiRienzo AG, Wilkin T, Fletcher CV, Margolis DM, Thal GD, Godfrey C, Bastow B, Ray MG, Wang H, Coombs RW, McKinnon J, Mellors JW; AIDS Clinical Trials Group 5201 Study Team.

JAMA. 2006 Aug 16;296(7):806-14.PMID: 16905786 [PubMed - indexed for MEDLINE]Related articlesFree article

Predictors of virologic and clinical outcomes in HIV-1-infected patients receiving concurrent treatment with indinavir, zidovudine, and lamivudine. AIDS Clinical Trials Group Protocol 320.

Demeter LM, Hughes MD, Coombs RW, Jackson JB, Grimes JM, Bosch RJ, Fiscus SA, Spector SA, Squires KE, Fischl MA, Hammer SM.

Ann Intern Med. 2001 Dec 4;135(11):954-64.PMID: 11730396 [PubMed - indexed for MEDLINE]Related articlesFree article

Monitoring plasma HIV-1 RNA levels in addition to CD4+ lymphocyte count improves assessment of antiretroviral therapeutic response. ACTG 241 Protocol Virology Substudy Team.

Hughes MD, Johnson VA, Hirsch MS, Bremer JW, Elbeik T, Erice A, Kuritzkes DR, Scott WA, Spector SA, Basgoz N, Fischl MA, D'Aquila RT.

Ann Intern Med. 1997 Jun 15;126(12):929-38.PMID: 9182469 [PubMed - indexed for MEDLINE]Related articlesFree article

Incidence and predictors of virologic failure of antiretroviral triple-drug therapy in a community-based cohort.

Paris D, Ledergerber B, Weber R, Jost J, Flepp M, Opravil M, Ruef C, Zimmerli S.

AIDS Res Hum Retroviruses. 1999 Dec 10;15(18):1631-8.PMID: 10606086 [PubMed - indexed for MEDLINE]Related articles

Highly active antiretroviral therapy outcomes in a primary care clinic.

Rastegar DA, Fingerhood MI, Jasinski DR.

AIDS Care. 2003 Apr;15(2):231-7.PMID: 12856344 [PubMed - indexed for MEDLINE]Related articles

Survival in an urban HIV-1 clinic in the era of highly active antiretroviral therapy: a 5-year cohort study.

Lucas GM, Chaisson RE, Moore RD.

J Acquir Immune Defic Syndr. 2003 Jul 1;33(3):321-8.PMID: 12843742 [PubMed - indexed for MEDLINE]Related articles

Outcome of a second-line protease inhibitor-containing regimen in patients failing or intolerant of a first highly active antiretroviral therapy.

Bini T, Testa L, Chiesa E, Adorni F, Abeli C, Castelnuovo B, Melzi S, Sollima S, Bongiovanni M, d'Arminio Monforte A.

J Acquir Immune Defic Syndr. 2000 Jun 1;24(2):115-22.PMID: 10935686 [PubMed - indexed for MEDLINE]Related articles

Virological suppression at 6 months is related to choice of initial regimen in antiretroviral-naive patients: a cohort study.

Matthews GV, Sabin CA, Mandalia S, Lampe F, Phillips AN, Nelson MR, Bower M, Johnson MA, Gazzard BG.

AIDS. 2002 Jan 4;16(1):53-61.PMID: 11741163 [PubMed - indexed for MEDLINE]Related articles

Duration and predictors of CD4 T-cell gains in patients who continue combination therapy despite detectable plasma viremia.

Deeks SG, Barbour JD, Grant RM, Martin JN.

AIDS. 2002 Jan 25;16(2):201-7.PMID: 11807304 [PubMed - indexed for MEDLINE]Related articles